Stay updated with the latest stock market news and insights
Weekly insights + SMS alerts
Health regulators have slapped Boston Scientific with the most serious recall designation there is. The company's Infinion CX Lead, a key part of its Spinal Cord Stimulator System used to treat chronic limb and back pain, is being pulled back due to a risk of fracture.
The U.S. Food and Drug Administration (FDA) issued the advisory on Thursday, and it's not messing around. The agency warns that continued use of these defective products could lead to "serious patient harm or death."
Boston Scientific has sent urgent notices to its customers, telling them to pull all unused devices from shelves and clinical settings immediately. Facilities must stop distributing or implanting the leads right away, quarantine what's left, and ship it back to the company.
Hospitals and clinics also need to spread the word internally to anyone who might handle these devices, and alert any outside facilities that may have received transferred units.
Here's the important nuance: this recall only affects inventory that hasn't been implanted yet. If you're a patient who already has one of these leads in place, you don't need to rush to the doctor for extra checks. Standard follow-up care is all that's required.
So what's going wrong? The issue comes down to mechanical stress at the anchor site where the lead attaches to the spinal cord stimulator system. That stress can cause the lead to fracture or create abnormally high impedance readings.
When impedance goes haywire, patients might not get the pain relief they need, or they could end up needing another surgery to remove and replace the lead entirely.
Before the recall was announced, Boston Scientific had already logged 1,081 serious injuries tied to these defects, as of May 27, 2026. The company says no deaths have been reported in connection with the problem.
Shares of Boston Scientific (BSX) were up 1.77% to $47.78 at the time of publication on Friday, according to market data.
Real-time alerts on price moves, news, and trading opportunities.
Join 20,000+ investors. No spam, ever.
